<DOC>
	<DOCNO>NCT00128258</DOCNO>
	<brief_summary>This research study perform find information safety effectiveness inject bone marrow progenitor cell ( BMPCs ) one 's hip bone one 's heart muscle . The BMPCs cell different type blood cell grow . In patient heart failure , heart muscle pump well . Over period year , continue get bad patient dy heart failure . The investigator try find injection BMPCs make change function area heart muscle . Data study around world suggest patient heart failure receive cell direct injection hearts show sign recover heart function , however , evidence actual study cell patient 's heart show process work . It investigator 's plan inject eligible participant 's heart cell one 's bone marrow operation receive ventricular assist device ( VAD ) partial artificial heart study function heart await heart transplant . The investigator examine heart remove part regular heart transplant operation microscopic change ( change small see unaided eye large enough study microscope ) site cell inject . Participants change chance receive heart transplant agree participate study . There also delay receive VAD operation wait participate study . This Phase I study clear Food Drug Administration ( FDA ) enroll treat patient . The Center Biologics Evaluation Research Investigational New Drug number ( IND BB # ) 12304 . ( A Phase I trial research study use technique product first-stage first time human subject ) .</brief_summary>
	<brief_title>Autologous/Allogeneic Progenitor Stem Cell Therapy Congestive Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Age &gt; =18 year . Congestive heart failure ejection fraction &lt; = 35 . Candidates ventricular device placement bridge transplant . Serum bilirubin , SGOT SGPT &lt; = 2.5 time upper level normal . Serum creatinine &lt; 2.0 time normal dialysis . New York Heart Association ( NYHA ) performance status &gt; 3 . Negative pregnancy test ( woman childbearing potential ) . Pregnant breastfeed woman . History prior radiation exposure . History bone marrow disorder . History abnormal bleeding clotting . History liver cirrhosis . Inability obtain 1 x 10^6 CD 34+ cell bone marrow processing . Acute myocardial infarction &lt; 6 day acute event . Prior malignancy 5 year treatment study ( curatively treat carcinoma insitu cervix nonmelanoma skin cancer ) . Inability unwillingness comply treatment protocol , followup , research test , give consent . Eligible destination ventricular assist device placement . Unable 250cc bone marrow harvest .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Stem Cell</keyword>
	<keyword>Heart Failure</keyword>
	<keyword>Bone Marrow</keyword>
</DOC>